No Data
No Data
No Data
No Data
No Data
CGC, GENE and HOLO Among Mid-day Movers
Seeking AlphaApr 19 00:42
Aileron Therapeutics Filed U.S. Patent Application #20240124518: Methods For Preparing Purified Polypeptide Compositions
Aileron Therapeutics Filed U.S. Patent Application #20240124518: Methods For Preparing Purified Polypeptide Compositions
BenzingaApr 18 23:50
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Las Vegas Sands Corp. (NYSE:LVS) fell sharply during Thursday's session despite better-than-expected first-quarter results.The company reported quarterly adjusted earnings of 75 cents per sh
BenzingaApr 18 23:32
Veru, EyePoint Pharmaceuticals, SINTX Technologies Among Healthcare Movers
Seeking AlphaApr 18 22:00
Ladenburg Thalmann: Maintaining the Aileron Therapeutics (ALRN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $19.00.
Ladenburg Thalmann: Maintaining the Aileron Therapeutics (ALRN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $19.00.
Zhitong FinanceApr 18 20:40
Ladenburg Thalmann Maintains Buy on Aileron Therapeutics, Raises Price Target to $19
Ladenburg Thalmann analyst Aydin Huseynov maintains Aileron Therapeutics with a Buy and raises the price target from $9 to $19.
Analyst UpgradesApr 18 20:36
No Data
No Data